Coloplast A/S reaffirmed earnings guidance for the fiscal year 2023/24. For the year, the organic revenue growth is still expected around 8% and continues to assume good momentum across business areas and regions.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
848.8 DKK | -0.07% |
|
+3.71% | +9.95% |
06-06 | Transcript : Coloplast A/S - Analyst/Investor Day | |
05-15 | COLOPLAST : Multiple silver linings in spite of a soft Q2 24 | ![]() |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.95% | 27.41B | |
+21.48% | 2.36B | |
+13.31% | 2.27B | |
-48.88% | 2.2B | |
-30.74% | 2.03B | |
+21.11% | 1.84B | |
-15.10% | 1.7B | |
+6.58% | 1.34B | |
+16.77% | 1.24B | |
+27.03% | 1.24B |
- Stock Market
- Equities
- COLO B Stock
- News Coloplast A/S
- Coloplast A/S Reaffirms Earnings Guidance for the Fiscal Year 2023/24